CLRB Stock CLRB is expected to report earnings to rise+83% to -53 cents per share on May 14

A.I.dvisor
at Tickeron.com
05/13/24
Loading...
CLRB - Cellectar Biosciences
Cellectar Biosciences Earnings Graph
Q1'24
Est.
$-0.53
Q4'23
Missed
by $2.58
Q3'23
Missed
by $0.64
Q2'23
Missed
by $0.09
Q1'23
Beat
by $0.07
The last earnings report on December 31 showed earnings per share of -311 cents, missing the estimate of -53 cents. P/B Ratio (0.000) is normal, around the industry mean (10.609). P/E Ratio (0.000) is within average values for comparable stocks, (160.883). CLRB's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.422). Dividend Yield (0.000) settles around the average of (0.066) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (236.959). With 1.12M shares outstanding, the current market capitalization sits at 110.06M.
View a ticker or compare two or three
CLRBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company that is engaged in developing compounds for the treatment and imaging of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
100 Campus Drive
Phone
+1 608 441-8120
Employees
20
Web
https://www.cellectar.com